{"name":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","slug":"translational-research-center-for-medical-innovation-kobe-hyogo-japan","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Asprin, Cilostazol","genericName":"Asprin, Cilostazol","slug":"asprin-cilostazol","indication":"Secondary prevention of cardiovascular events in patients with peripheral arterial disease or coronary artery disease","status":"phase_3"},{"name":"tacrolimus + mycophenolate mofetil","genericName":"tacrolimus + mycophenolate mofetil","slug":"tacrolimus-mycophenolate-mofetil","indication":"Organ transplant rejection prevention (likely kidney, heart, or liver transplantation)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Non-PPI (Gefarnate)","genericName":"Non-PPI (Gefarnate)","slug":"non-ppi-gefarnate","indication":"Gastric ulcer","status":"phase_3"},{"name":"tacrolimus + steroid","genericName":"tacrolimus + steroid","slug":"tacrolimus-steroid","indication":"Prophylaxis of organ rejection in patients receiving allogeneic organ transplants","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"UFT adjuvant chemotherapy","genericName":"UFT adjuvant chemotherapy","slug":"uft-adjuvant-chemotherapy","indication":"Adjuvant chemotherapy for colorectal cancer","status":"phase_3"}]}],"pipeline":[{"name":"Asprin, Cilostazol","genericName":"Asprin, Cilostazol","slug":"asprin-cilostazol","phase":"phase_3","mechanism":"This combination of aspirin (antiplatelet) and cilostazol (phosphodiesterase-3 inhibitor) works synergistically to inhibit platelet aggregation and improve blood flow.","indications":["Secondary prevention of cardiovascular events in patients with peripheral arterial disease or coronary artery disease","Stroke prevention"],"catalyst":""},{"name":"Non-PPI (Gefarnate)","genericName":"Non-PPI (Gefarnate)","slug":"non-ppi-gefarnate","phase":"phase_3","mechanism":"Gefarnate is a mucoprotective agent that enhances gastric mucus production and strengthens the gastric mucosal barrier to protect against acid-induced damage.","indications":["Gastric ulcer","Duodenal ulcer","Gastritis"],"catalyst":""},{"name":"UFT adjuvant chemotherapy","genericName":"UFT adjuvant chemotherapy","slug":"uft-adjuvant-chemotherapy","phase":"phase_3","mechanism":"UFT is a combination of uracil and tegafur (a prodrug of fluorouracil) that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.","indications":["Adjuvant chemotherapy for colorectal cancer","Gastric cancer adjuvant treatment"],"catalyst":""},{"name":"tacrolimus + mycophenolate mofetil","genericName":"tacrolimus + mycophenolate mofetil","slug":"tacrolimus-mycophenolate-mofetil","phase":"phase_3","mechanism":"This combination suppresses T-cell activation and proliferation through calcineurin inhibition (tacrolimus) and inosine monophosphate dehydrogenase inhibition (mycophenolate mofetil) to prevent organ rejection.","indications":["Organ transplant rejection prevention (likely kidney, heart, or liver transplantation)"],"catalyst":""},{"name":"tacrolimus + steroid","genericName":"tacrolimus + steroid","slug":"tacrolimus-steroid","phase":"phase_3","mechanism":"Tacrolimus is an immunosuppressant that inhibits calcineurin, a protein phosphatase involved in the activation of T-lymphocytes, while steroids reduce inflammation and suppress the immune system.","indications":["Prophylaxis of organ rejection in patients receiving allogeneic organ transplants"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}